Prolieve Thermodilatation System
Commercial- Indications
- Benign Prostatic Hyperplasia
Company intelligence / Profile preview
Medifocus has commercialized the Prolieve® Thermodilatation™ System for BPH and is developing focused microwave thermotherapy and heat-triggered gene therapy platforms for cancer. The company has exclusive licenses from Duke University to develop tumor-targeting, heat‑activated immunotherapeutics such as IL‑12 gene delivery constructs. Clinical results indicate effective symptom relief in BPH with minimal side effects; oncology programs are earlier stage.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Medifocus.